Add-on Acquisition • Life Science

Pyxis Oncology Acquires Apexigen

On August 23, 2023, Pyxis Oncology acquired life science company Apexigen

Acquisition Context

This is Pyxis Oncology’s 1st transaction in the Life Science sector.
This is Pyxis Oncology’s 1st transaction in the United States.
This is Pyxis Oncology’s 1st transaction in California.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	August 23, 2023
Target	Apexigen
Sector	Life Science
Buyer(s)	Pyxis Oncology
Deal Type	Add-on Acquisition
Advisor(s)	Ladenburg Thalmann & Co. (Financial) Wilson Sonsini Goodrich & Rosati (Legal)

Target Company

Apexigen

San Carlos, California, United States

Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is currently in clinical development, and also includes several preclinical stage immune-oncology programs. Apexigen was founded in 2010 and is based in San Carlos, California.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Pyxis Oncology

Boston, Massachusetts, United States

Category	Company
Founded	2018
Sector	Life Science
Employees	44
Revenue	16M USD (2024)

DESCRIPTION

Pyxis Oncology specializes in developing a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis Oncology was founded in 2018 and is based in Boston, Massachusetts.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: California	1 of 1
Country: United States	1 of 1
Year: 2023	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - California M&A - United States M&A - 2023 M&A